Novartis and MMV’s Coartem shows promise in infants with Phase II/III data
Novartis and MMV’s Coartem formulation for infants weighing 5kg met the primary endpoint in Phase II/III trial of infants and neonates with malaria.
25 April 2024
25 April 2024
Novartis and MMV’s Coartem formulation for infants weighing 5kg met the primary endpoint in Phase II/III trial of infants and neonates with malaria.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.